Autonomic control of ventricular function in health and disease: current state of the art

1.

Ardell JL, Armour JA (2016) Neurocardiology: structure-based function. Compr Physiol 6:1635–1653. https://doi.org/10.1002/cphy.c150046CrossRefPubMed

2.

Armour JA (2004) Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol 287:R262-271. https://doi.org/10.1152/ajpregu.00183.2004CrossRefPubMed

3.

Armour JA, Huang MH, Pelleg A, Sylven C (1994) Responsiveness of in situ canine nodose ganglion afferent neurones to epicardial mechanical or chemical stimuli. Cardiovasc Res 28:1218–1225. https://doi.org/10.1093/cvr/28.8.1218CrossRefPubMed

4.

Du X, Hao H, Yang Y, Huang S, Wang C, Gigout S, Ramli R, Li X, Jaworska E, Edwards I, Deuchars J, Yanagawa Y, Qi J, Guan B, Jaffe DB, Zhang H, Gamper N (2017) Local GABAergic signaling within sensory ganglia controls peripheral nociceptive transmission. J Clin Invest 127:1741–1756. https://doi.org/10.1172/JCI86812CrossRefPubMedPubMedCentral

5.

Hanack C, Moroni M, Lima WC, Wende H, Kirchner M, Adelfinger L, Schrenk-Siemens K, Tappe-Theodor A, Wetzel C, Kuich PH, Gassmann M, Roggenkamp D, Bettler B, Lewin GR, Selbach M, Siemens J (2015) GABA blocks pathological but not acute TRPV1 pain signals. Cell 160:759–770. https://doi.org/10.1016/j.cell.2015.01.022CrossRefPubMed

6.

Pagadala P, Park CK, Bang S, Xu ZZ, Xie RG, Liu T, Han BX, Tracey WD Jr, Wang F, Ji RR (2013) Loss of NR1 subunit of NMDARs in primary sensory neurons leads to hyperexcitability and pain hypersensitivity: involvement of Ca(2+)-activated small conductance potassium channels. J Neurosci 33:13425–13430. https://doi.org/10.1523/JNEUROSCI.0454-13.2013CrossRefPubMedPubMedCentral

7.

Zhu Y, Lu SG, Gold MS (2012) Persistent inflammation increases GABA-induced depolarization of rat cutaneous dorsal root ganglion neurons in vitro. Neuroscience 220:330–340. https://doi.org/10.1016/j.neuroscience.2012.06.025CrossRefPubMed

8.

Janig W (2006) Integrative action of the autonomic nervous system: neurobiology of homeostasis. Cambridge University Press, CambridgeCrossRef

9.

Salavatian S, Hoang JD, Yamaguchi N, Lokhandwala ZA, Swid MA, Armour JA, Ardell JL, Vaseghi M (2022) Myocardial infarction reduces cardiac nociceptive neurotransmission through the vagal ganglia. JCI Insight 7:e155747. https://doi.org/10.1172/jci.insight.155747CrossRefPubMedPubMedCentral

10.

Hopkins DA, Armour JA (1989) Ganglionic distribution of afferent neurons innervating the canine heart and cardiopulmonary nerves. J Auton Nerv Syst 26:213–222. https://doi.org/10.1016/0165-1838(89)90170-7CrossRefPubMed

11.

Malliani A, Montano N (2002) Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension 39:63–68. https://doi.org/10.1161/hy0102.099200CrossRefPubMed

12.

Wang HJ, Rozanski GJ, Zucker IH (2017) Cardiac sympathetic afferent reflex control of cardiac function in normal and chronic heart failure states. J Physiol 595:2519–2534. https://doi.org/10.1113/JP273764CrossRefPubMedPubMedCentral

13.

Armour JA, Ardell JL (2004) Basic and clinical neurocardiology. Oxford University Press, New York

14.

Chapleau MW, Hajduczok G, Sharma RV, Wachtel RE, Cunningham JT, Sullivan MJ, Abboud FM (1995) Mechanisms of baroreceptor activation. Clin Exp Hypertens 17:1–13. https://doi.org/10.3109/10641969509087050CrossRefPubMed

15.

Kirchheim HR (1976) Systemic arterial baroreceptor reflexes. Physiol Rev 56:100–177. https://doi.org/10.1152/physrev.1976.56.1.100CrossRefPubMed

16.

Guyenet PG (2014) Regulation of breathing and autonomic outflows by chemoreceptors. Compr Physiol 4:1511–1562. https://doi.org/10.1002/cphy.c140004CrossRefPubMedPubMedCentral

17.

Kumar P, Prabhakar NR (2012) Peripheral chemoreceptors: function and plasticity of the carotid body. Compr Physiol 2:141–219. https://doi.org/10.1002/cphy.c100069CrossRefPubMedPubMedCentral

18.

Schultz HD, Marcus NJ, Del Rio R (2015) Role of the carotid body chemoreflex in the pathophysiology of heart failure: a perspective from animal studies. Adv Exp Med Biol 860:167–185. https://doi.org/10.1007/978-3-319-18440-1_19CrossRefPubMed

19.

Bosnjak ZJ, Kampine JP (1989) Cardiac sympathetic afferent cell bodies are located in the peripheral nervous system of the cat. Circ Res 64:554–562. https://doi.org/10.1161/01.res.64.3.554CrossRefPubMed

20.

Kirchberber MA, Tada M, Katz AM (1975) Phospholamban: a regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv Stud Cardiac Struct Metab 5:103–115PubMed

21.

Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219–226. https://doi.org/10.1038/415219aCrossRefPubMed

22.

Shannon TR, Ginsburg KS, Bers DM (2000) Potentiation of fractional sarcoplasmic reticulum calcium release by total and free intra-sarcoplasmic reticulum calcium concentration. Biophys J 78:334–343. https://doi.org/10.1016/S0006-3495(00)76596-9CrossRefPubMedPubMedCentral

23.

Viatchenko-Karpinski S, Gyorke S (2001) Modulation of the Ca(2+)-induced Ca(2+) release cascade by beta-adrenergic stimulation in rat ventricular myocytes. J Physiol 533:837–848. https://doi.org/10.1111/j.1469-7793.2001.t01-1-00837.xCrossRefPubMedPubMedCentral

24.

Bucchi A, Baruscotti M, Robinson RB, DiFrancesco D (2007) Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J Mol Cell Cardiol 43:39–48. https://doi.org/10.1016/j.yjmcc.2007.04.017CrossRefPubMed

25.

Bogdanov KY, Maltsev VA, Vinogradova TM, Lyashkov AE, Spurgeon HA, Stern MD, Lakatta EG (2006) Membrane potential fluctuations resulting from submembrane Ca2+ releases in rabbit sinoatrial nodal cells impart an exponential phase to the late diastolic depolarization that controls their chronotropic state. Circ Res 99:979–987. https://doi.org/10.1161/01.RES.0000247933.66532.0bCrossRefPubMed

26.

Lakatta EG, Maltsev VA, Vinogradova TM (2010) A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart’s pacemaker. Circ Res 106:659–673. https://doi.org/10.1161/CIRCRESAHA.109.206078CrossRefPubMedPubMedCentral

27.

Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S, Yang D, Deo S, Barlow M, Johnson S, Caffrey JL, Zhou YY, Xiao RP, Cheng H, Stern MD, Maltsev VA, Lakatta EG (2006) High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res 98:505–514. https://doi.org/10.1161/01.RES.0000204575.94040.d1CrossRefPubMed

28.

Li L, Desantiago J, Chu G, Kranias EG, Bers DM (2000) Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol 278:H769-779. https://doi.org/10.1152/ajpheart.2000.278.3.H769CrossRefPubMed

29.

Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ (2001) Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res 88:1059–1065. https://doi.org/10.1161/hh1001.091640CrossRefPubMed

30.

Marx SO, Kurokawa J, Reiken S, Motoike H, D’Armiento J, Marks AR, Kass RS (2002) Requirement of a macromolecular signaling complex for beta-adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 295:496–499. https://doi.org/10.1126/science.1066843CrossRefPubMed

31.

Chiamvimonvat N, Chen-Izu Y, Clancy CE, Deschenes I, Dobrev D, Heijman J, Izu L, Qu Z, Ripplinger CM, Vandenberg JI, Weiss JN, Koren G, Banyasz T, Grandi E, Sanguinetti MC, Bers DM, Nerbonne JM (2017) Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. J Physiol 595:2229–2252. https://doi.org/10.1113/JP272883CrossRefPubMedPubMedCentral

32.

Burnstock G (2009) Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol 49:1–30. https://doi.org/10.1146/annurev.pharmtox.052808.102215CrossRefPubMed

33.

Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN, Girard BM, Carter E, Parsons RL, Habecker BA, Paterson DJ (2012) The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol 52:667–676. https://doi.org/10.1016/j.yjmcc.2011.11.016CrossRefPubMedPubMedCentral

34.

Heredia Mdel P, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, Benitah JP, Gomez AM (2005) Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol 38:205–212. https://doi.org/10.1016/j.yjmcc.2004.11.001CrossRefPubMed

35.

Hoang JD, Salavatian S, Yamaguchi N, Swid MA, David H, Vaseghi M (2020) Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y. JCI Insight 5:e135519. https://doi.org/10.1172/jci.insight.135519CrossRefPubMedPubMedCentral

36.

Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ (2008) Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 44:477–485. https://doi.org/10.1016/j.yjmcc.2007.10.001CrossRefPubMed

37.

Opthof T, Misier AR, Coronel R, Vermeulen JT, Verberne HJ, Frank RG, Moulijn AC, van Capelle FJ, Janse MJ (1991) Dispersion of refractoriness in canine ventricular myocardium. Effects of sympathetic stimulation. Circ Res 68:1204–1215. https://doi.org/10.1161/01.res.68.5.1204CrossRefPubMed

38.

Yanowitz F, Preston JB, Abildskov JA (1966) Functional distribution of right and left stellate innervation to the ventricles. Production of neurogenic electrocardiographic changes by unilateral alteration of sympathetic tone. Circ Res 18:416–428. https://doi.org/10.1161/01.res.18.4.416CrossRefPubMed

39.

Cinca J, Evangelista A, Montoyo J, Barutell C, Figueras J, Valle V, Rius J, Soler-Soler J (1985) Electrophysiologic effects of unilateral right and left stellate ganglion block on the human heart. Am Heart J 109:46–54. https://doi.org/10.1016/0002-8703(85)90414-4CrossRefPubMed

40.

Rogers MC, Battit G, McPeek B, Todd D (1978) Lateralization of sympathetic control of the human sinus node: ECG changes of stellate ganglion block. Anesthesiology 48:139–141. https://doi.org/10.1097/00000542-197802000-00009CrossRefPubMed

41.

Schlack W, Thamer V (1996) Unilateral changes of sympathetic tone to the heart impair left ventricular function. Acta Anaesthesiol Scand 40:262–271. https://doi.org/10.1111/j.1399-6576.1996.tb04430.xCrossRefPubMed

42.

Vaseghi M, Zhou W, Shi J, Ajijola OA, Hadaya J, Shivkumar K, Mahajan A (2012) Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm 9:1303–1309. https://doi.org/10.1016/j.hrthm.2012.03.052CrossRefPubMed

43.

Armour JA (2008) Potential clinical relevance of the ‘little brain’ on the mammalian heart. Exp Physiol 93:165–176. https://doi.org/10.1113/expphysiol.2007.041178CrossRefPubMed

44.

Agostoni E, Chinnock JE, De Daly MB, Murray JG (1957) Functional and histological studies of the vagus nerve and its branches to the heart, lungs and abdominal viscera in the cat. J Physiol 135:182–205. https://doi.org/10.1113/jphysiol.1957.sp005703CrossRefPubMedPubMedCentral

45.

Brodde OE, Bruck H, Leineweber K, Seyfarth T (2001) Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 96:528–538. https://doi.org/10.1007/s003950170003CrossRefPubMed

46.

Yamakawa K, So EL, Rajendran PS, Hoang JD, Makkar N, Mahajan A, Shivkumar K, Vaseghi M (2014) Electrophysiological effects of right and left vagal nerve stimulation on the ventricular myocardium. Am J Physiol Heart Circ Physiol 307:H722-731. https://doi.org/10.1152/ajpheart.00279.2014CrossRefPubMedPubMedCentral

47.

Han SY, Bolter CP (2015) Effects of tertiapin-Q and ZD7288 on changes in sinoatrial pacemaker rhythm during vagal stimulation. Auton Neurosci 193:117–126. https://doi.org/10.1016/j.autneu.2015.10.002CrossRefPubMed

48.

Krapivinsky G, Krapivinsky L, Wickman K, Clapham DE (1995) G beta gamma binds directly to the G protein-gated K+ channel, IKACh. J Biol Chem 270:29059–29062. https://doi.org/10.1074/jbc.270.49.29059CrossRefPubMed

49.

Manabe N, Foldes FF, Torocsik A, Nagashima H, Goldiner PL, Vizi ES (1991) Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 32:233–242. https://doi.org/10.1016/0165-1838(91)90117-lCrossRefPubMed

50.

Loffelholz K, Muscholl E (1969) A muscarinic inhibition of the noradrenaline release evoked by postganglionic sympathetic nerve stimulation. Naunyn Schmiedebergs Arch Pharmakol 265:1–15. https://doi.org/10.1007/BF01417206CrossRefPubMed

51.

Ishibashi H, Umezu M, Jang IS, Ito Y, Akaike N (2003) Alpha 1-adrenoceptor-activated cation currents in neurones acutely isolated from rat cardiac parasympathetic ganglia. J Physiol 548:111–120. https://doi.org/10.1113/jphysiol.2002.033100CrossRefPubMedPubMedCentral

52.

Christophe J, Waelbroeck M, Chatelain P, Robberecht P (1984) Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology. Peptides 5:341–353. https://doi.org/10.1016/0196-9781(84)90232-8CrossRefPubMed

53.

De Neef P, Robberecht P, Chatelain P, Waelbroeck M, Christophe J (1984) The in vitro chronotropic and inotropic effects of vasoactive intestinal peptide (VIP) on the atria and ventricular papillary muscle from Cynomolgus monkey heart. Regul Pept 8:237–244. https://doi.org/10.1016/0167-0115(84)90065-xCrossRefPubMed

54.

Rigel DF (1988) Effects of neuropeptides on heart rate in dogs: comparison of VIP, PHI, NPY, CGRP, and NT. Am J Physiol 255:H311-317. https://doi.org/10.1152/ajpheart.1988.255.2.H311CrossRefPubMed

55.

Hogan K, Markos F (2006) Vasoactive intestinal polypeptide receptor antagonism enhances the vagally induced increase in cardiac interval of the rat atrium in vitro. Exp Physiol 91:641–646. https://doi.org/10.1113/expphysiol.2006.033605CrossRefPubMed

56.

Danson EJ, Choate JK, Paterson DJ (2005) Cardiac nitric oxide: emerging role for nNOS in regulating physiological function. Pharmacol Ther 106:57–74. https://doi.org/10.1016/j.pharmthera.2004.11.003CrossRefPubMed

57.

Wang W, Schultz HD, Ma R (1999) Cardiac sympathetic afferent sensitivity is enhanced in heart failure. Am J Physiol 277:H812-817. https://doi.org/10.1152/ajpheart.1999.277.2.H812CrossRefPubMed

58.

Ma R, Zucker IH, Wang W (1999) Reduced NO enhances the central gain of cardiac sympathetic afferent reflex in dogs with heart failure. Am J Physiol 276:H19-26. https://doi.org/10.1152/ajpheart.1999.276.1.H19CrossRefPubMed

59.

Patel KP, Zhang K, Zucker IH, Krukoff TL (1996) Decreased gene expression of neuronal nitric oxide synthase in hypothalamus and brainstem of rats in heart failure. Brain Res 734:109–115. https://doi.org/10.1016/0006-8993(96)00620-8CrossRefPubMed

60.

Nakamura K, Ajijola OA, Aliotta E, Armour JA, Ardell JL, Shivkumar K (2016) Pathological effects of chronic myocardial infarction on peripheral neurons mediating cardiac neurotransmission. Auton Neurosci 197:34–40. https://doi.org/10.1016/j.autneu.2016.05.001CrossRefPubMedPubMedCentral

61.

Wang HJ, Wang W, Cornish KG, Rozanski GJ, Zucker IH (2014) Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. Hypertension 64:745–755. https://doi.org/10.1161/HYPERTENSIONAHA.114.03699CrossRefPubMed

62.

Yoshie K, Rajendran PS, Massoud L, Mistry J, Swid MA, Wu X, Sallam T, Zhang R, Goldhaber JI, Salavatian S, Ajijola OA (2020) Cardiac TRPV1 afferent signaling promotes arrhythmogenic ventricular remodeling after myocardial infarction. JCI Insight 5:e124477. https://doi.org/10.1172/jci.insight.124477CrossRefPubMedPubMedCentral

63.

Rajendran PS, Nakamura K, Ajijola OA, Vaseghi M, Armour JA, Ardell JL, Shivkumar K (2016) Myocardial infarction induces structural and functional remodelling of the intrinsic cardiac nervous system. J Physiol 594:321–341. https://doi.org/10.1113/JP271165CrossRefPubMed

64.

Ajijola OA, Hoover DB, Simerly TM, Brown TC, Yanagawa J, Biniwale RM, Lee JM, Sadeghi A, Khanlou N, Ardell JL, Shivkumar K (2017) Inflammation, oxidative stress, and glial cell activation characterize stellate ganglia from humans with electrical storm. JCI Insight 2:e94715. https://doi.org/10.1172/jci.insight.94715CrossRefPubMedPubMedCentral

65.

Han S, Kobayashi K, Joung B, Piccirillo G, Maruyama M, Vinters HV, March K, Lin SF, Shen C, Fishbein MC, Chen PS, Chen LS (2012) Electroanatomic remodeling of the left stellate ganglion after myocardial infarction. J Am Coll Cardiol 59:954–961. https://doi.org/10.1016/j.jacc.2011.11.030CrossRefPubMedPubMedCentral

66.

Bardsley EN, Paterson DJ (2020) Neurocardiac regulation: from cardiac mechanisms to novel therapeutic approaches. J Physiol 598:2957–2976. https://doi.org/10.1113/JP276962CrossRefPubMed

67.

Davis H, Herring N, Paterson DJ (2020) Downregulation of M current is coupled to membrane excitability in sympathetic neurons before the onset of hypertension. Hypertension 76:1915–1923. https://doi.org/10.1161/HYPERTENSIONAHA.120.15922CrossRefPubMed

68.

Wang L, Li D, Plested CP, Dawson T, Teschemacher AG, Paterson DJ (2006) Noradrenergic neuron-specific overexpression of nNOS in cardiac sympathetic nerves decreases neurotransmission. J Mol Cell Cardiol 41:364–370. https://doi.org/10.1016/j.yjmcc.2006.05.007CrossRefPubMed

69.

Schwarz P, Diem R, Dun NJ, Forstermann U (1995) Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 77:841–848. https://doi.org/10.1161/01.res.77.4.841CrossRefPubMed

70.

Balligand JL (1999) Regulation of cardiac beta-adrenergic response by nitric oxide. Cardiovasc Res 43:607–620. https://doi.org/10.1016/s0008-6363(99)00163-7CrossRefPubMed

71.

Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, Endo J, Sano M, Kawakami T, Kimura T, Monkawa T, Hayashi M, Iwanami A, Okano H, Okada Y, Ishibashi-Ueda H, Ogawa S, Fukuda K (2010) Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 120:408–421. https://doi.org/10.1172/JCI39778CrossRefPubMedPubMedCentral

72.

Olivas A, Gardner RT, Wang L, Ripplinger CM, Woodward WR, Habecker BA (2016) Myocardial infarction causes transient cholinergic transdifferentiation of cardiac sympathetic nerves via gp130. J Neurosci 36:479–488. https://doi.org/10.1523/JNEUROSCI.3556-15.2016CrossRefPubMedPubMedCentral

73.

Clyburn C, Andresen MC, Ingram SL, Habecker BA (2022) Untangling peripheral sympathetic neurocircuits. Front Cardiovasc Med 9:842656. https://doi.org/10.3389/fcvm.2022.842656CrossRefPubMedPubMedCentral

74.

Clyburn C, Li MH, Ingram SL, Andresen MC, Habecker BA (2023) Cholinergic collaterals arising from noradrenergic sympathetic neurons in mice. J Physiol. https://doi.org/10.1113/JP284059CrossRefPubMed

75.

Liang CS (2007) Cardiac sympathetic nerve terminal function in congestive heart failure. Acta Pharmacol Sin 28:921–927. https://doi.org/10.1111/j.1745-7254.2007.00585.xCrossRefPubMed

76.

Kimura K, Ieda M, Kanazawa H, Yagi T, Tsunoda M, Ninomiya S, Kurosawa H, Yoshimi K, Mochizuki H, Yamazaki K, Ogawa S, Fukuda K (2007) Cardiac sympathetic rejuvenation: a link between nerve function and cardiac hypertrophy. Circ Res 100:1755–1764. https://doi.org/10.1161/01.RES.0000269828.62250.abCrossRefPubMed

77.

Chidsey CA, Harrison DC, Braunwald E (1962) Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 267:650–654. https://doi.org/10.1056/NEJM196209272671305CrossRefPubMed

78.

Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49:1659–1666. https://doi.org/10.1016/0002-9149(82)90243-0CrossRefPubMed

79.

Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41:233–243. https://doi.org/10.1016/0002-9149(78)90162-5CrossRefPubMed

80.

Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667–1676. https://doi.org/10.1161/01.cir.93.9.1667CrossRefPubMed

81.

Gibbs T, Tapoulal N, Shanmuganathan M, Burrage MK, Borlotti A, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Ferreira VM, Channon KM, Herring N, Ox AMIS (2022) Neuropeptide-Y levels in ST-segment-elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality. J Am Heart Assoc 11:e024850. https://doi.org/10.1161/JAHA.121.024850CrossRefPubMedPubMedCentral

82.

Kalla M, Hao G, Tapoulal N, Tomek J, Liu K, Woodward L, Oxford Acute Myocardial Infarction S, Dall’Armellina E, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Channon KM, Ajijola OA, Shivkumar K, Paterson DJ, Herring N (2020) The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J 41:2168–2179. https://doi.org/10.1093/eurheartj/ehz852CrossRefPubMed

83.

Ullman B, Hulting J, Lundberg JM (1994) Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 15:454–461. https://doi.org/10.1093/oxfordjournals.eurheartj.a060526CrossRefPubMed

84.

Cao JM, Chen LS, KenKnight BH, Ohara T, Lee MH, Tsai J, Lai WW, Karagueuzian HS, Wolf PL, Fishbein MC, Chen PS (2000) Nerve sprouting and sudden cardiac death. Circ Res 86:816–821. https://doi.org/10.1161/01.res.86.7.816CrossRefPubMed

85.

Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K (2015) Cardiac innervation and sudden cardiac death. Circ Res 116:2005–2019. https://doi.org/10.1161/CIRCRESAHA.116.304679CrossRefPubMedPubMedCentral

86.

Kaye DM, Vaddadi G, Gruskin SL, Du XJ, Esler MD (2000) Reduced myocardial nerve growth factor expression in human and experimental heart failure. Circ Res 86:E80-84. https://doi.org/10.1161/01.res.86.7.e80CrossRefPubMed

87.

Kimura K, Kanazawa H, Ieda M, Kawaguchi-Manabe H, Miyake Y, Yagi T, Arai T, Sano M, Fukuda K (2010) Norepinephrine-induced nerve growth factor depletion causes cardiac sympathetic denervation in severe heart failure. Auton Neurosci 156:27–35. https://doi.org/10.1016/j.autneu.2010.02.005CrossRefPubMed

88.

Gardner RT, Habecker BA (2013) Infarct-derived chondroitin sulfate proteoglycans prevent sympathetic reinnervation after cardiac ischemia-reperfusion injury. J Neurosci 33:7175–7183. https://doi.org/10.1523/JNEUROSCI.5866-12.2013CrossRefPubMedPubMedCentral

89.

Gardner RT, Wang L, Lang BT, Cregg JM, Dunbar CL, Woodward WR, Silver J, Ripplinger CM, Habecker BA (2015) Targeting protein tyrosine phosphatase sigma after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 6:6235. https://doi.org/10.1038/ncomms7235CrossRefPubMed

90.

Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87:454–463. https://doi.org/10.1161/01.cir.87.2.454CrossRefPubMed

91.

Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE, Gorelik J (2010) Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327:1653–1657. https://doi.org/10.1126/science.1185988CrossRefPubMed

92.

Desantiago J, Ai X, Islam M, Acuna G, Ziolo MT, Bers DM, Pogwizd SM (2008) Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res 102:1389–1397. https://doi.org/10.1161/CIRCRESAHA.107.169011CrossRefPubMedPubMedCentral

93.

Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D (2012) Targeting the beta-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 5:385–391. https://doi.org/10.1161/CIRCHEARTFAILURE.112.966895CrossRefPubMed

94.

Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1–24PubMed

95.

Reiter E, Lefkowitz RJ (2006) GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17:159–165. https://doi.org/10.1016/j.tem.2006.03.008CrossRefPubMed

96.

Xu B, Li M, Wang Y, Zhao M, Morotti S, Shi Q, Wang Q, Barbagallo F, Teoh JP, Reddy GR, Bayne EF, Liu Y, Shen A, Puglisi JL, Ge Y, Li J, Grandi E, Nieves-Cintron M, Xiang YK (2020) GRK5 controls SAP97-dependent cardiotoxic beta(1) adrenergic receptor-CaMKII signaling in heart failure. Circ Res 127:796–810. https://doi.org/10.1161/CIRCRESAHA.119.316319CrossRefPubMedPubMedCentral

97.

Gullestad L, Aass H, Ross H, Ueland T, Geiran O, Kjekshus J, Simonsen S, Fowler M, Kobilka B (1998) Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation. J Auton Nerv Syst 70:84–91. https://doi.org/10.1016/s0165-1838(98)00032-0CrossRefPubMed

98.

Callanan EY, Lee EW, Tilan JU, Winaver J, Haramati A, Mulroney SE, Zukowska Z (2007) Renal and cardiac neuropeptide Y and NPY receptors in a rat model of congestive heart failure. Am J Physiol Renal Physiol 293:F1811-1817. https://doi.org/10.1152/ajprenal.00191.2007CrossRefPubMed

99.

Bohm M, Diet F, Feiler G, Kemkes B, Erdmann E (1988) Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 12:357–364. https://doi.org/10.1097/00005344-198809000-00015CrossRefPubMed

100.

Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB (1988) Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 247:1039–1045PubMed

101.

Cohn JN (1993) The vasodilator-heart failure trials (V-HeFT). Mechanistic data from the VA cooperative studies introduction. Circulation 87:VI1-4PubMed

102.

Dhaliwal AS, Habib G, Deswal A, Verduzco M, Souchek J, Ramasubbu K, Aguilar D, Ma TS, Jneid HM, Bolos M, Bozkurt B (2009) Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol 104:270–275. https://doi.org/10.1016/j.amjcard.2009.03.030CrossRefPubMed

103.

Nass RD, Aiba T, Tomaselli GF, Akar FG (2008) Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat Clin Pract Cardiovasc Med 5:196–207. https://doi.org/10.1038/ncpcardio1130CrossRefPubMed

104.

Nattel S, Maguy A, Le Bouter S, Yeh YH (2007) Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87:425–456. https://doi.org/10.1152/physrev.00014.2006CrossRefPubMed

105.

Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Schalij MJ, Bax JJ (2010) Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 55:2769–2777. https://doi.org/10.1016/j.jacc.2009.12.066CrossRefPubMed

106.

Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM Jr (2017) Denervated myocardium is preferentially associated with sudden cardiac arrest in ischemic cardiomyopathy: a pilot competing risks analysis of cause-specific mortality. Circ Cardiovasc Imaging 10:e006446. https://doi.org/10.1161/CIRCIMAGING.117.006446CrossRefPubMedPubMedCentral

107.

Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63:141–149. https://doi.org/10.1016/j.jacc.2013.07.096CrossRefPubMed

108.

Vaseghi M, Lux RL, Mahajan A, Shivkumar K (2012) Sympathetic stimulation increases dispersion of repolarization in humans with myocardial infarction. Am J Physiol Heart Circ Physiol 302:H1838-1846. https://doi.org/10.1152/ajpheart.01106.2011CrossRefPubMedPubMedCentral

109.

Warner MR, Wisler PL, Hodges TD, Watanabe AM, Zipes DP (1993) Mechanisms of denervation supersensitivity in regionally denervated canine hearts. Am J Physiol 264:H815-820. https://doi.org/10.1152/ajpheart.1993.264.3.H815CrossRefPubMed

110.

Aflaki M, Qi XY, Xiao L, Ordog B, Tadevosyan A, Luo X, Maguy A, Shi Y, Tardif JC, Nattel S (2014) Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained beta-adrenergic activation in guinea pig hearts. Circ Res 114:993–1003. https://doi.org/10.1161/CIRCRESAHA.113.302982CrossRefPubMed

111.

Tapa S, Wang L, Francis Stuart SD, Wang Z, Jiang Y, Habecker BA, Ripplinger CM (2020) Adrenergic supersensitivity and impaired neural control of cardiac electrophysiology following regional cardiac sympathetic nerve loss. Sci Rep 10:18801. https://doi.org/10.1038/s41598-020-75903-yCrossRefPubMedPubMedCentral

112.

Vaseghi M, Salavatian S, Rajendran PS, Yagishita D, Woodward WR, Hamon D, Yamakawa K, Irie T, Habecker BA, Shivkumar K (2017) Parasympathetic dysfunction and antiarrhythmic effect of vagal nerve stimulation following myocardial infarction. JCI Insight 2:e86715. https://doi.org/10.1172/jci.insight.86715CrossRefPubMedPubMedCentral

113.

Lokhandwala Z, Devarajan A, Wang K, Shannon K, Tompkins JD, Vaseghi M (2021) Abstract: myocardial infarction selectively decreases cardiac vagal afferent neurotransmission: implications for mechanisms behind cardiac parasympathetic dysfunction. Circulation 144:A14090. https://doi.org/10.1161/circ.144.suppl_1.14090CrossRef

114.

Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P (2003) Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. Am J Physiol Heart Circ Physiol 285:H1632-1640. https://doi.org/10.1152/ajpheart.01051.2002CrossRefPubMed

115.

Mazzadi AN, Pineau J, Costes N, Le Bars D, Bonnefoi F, Croisille P, Porcher R, Chevalier P (2009) Muscarinic receptor upregulation in patients with myocardial infarction: a new paradigm. Circ Cardiovasc Imaging 2:365–372. https://doi.org/10.1161/CIRCIMAGING.108.822106CrossRefPubMed

116.

He B, Lu Z, He W, Wu L, Cui B, Hu X, Yu L, Huang C, Jiang H (2013) Effects of ganglionated plexi ablation on ventricular electrophysiological properties in normal hearts and after acute myocardial ischemia. Int J Cardiol 168:86–93. https://doi.org/10.1016/j.ijcard.2012.09.067CrossRefPubMed

117.

Jungen C, Scherschel K, Eickholt C, Kuklik P, Klatt N, Bork N, Salzbrunn T, Alken F, Angendohr S, Klene C, Mester J, Klocker N, Veldkamp MW, Schumacher U, Willems S, Nikolaev VO, Meyer C (2017) Disruption of cardiac cholinergic neurons enhances susceptibility to ventricular arrhythmias. Nat Commun 8:14155. https://doi.org/10.1038/ncomms14155CrossRefPubMedPubMedCentral

118.

Wu B, Xu S, Dai R, Hong M, Wu H, Lin R (2019) Epicardial ganglionated plexi ablation increases the inducibility of ventricular tachyarrhythmias in a canine postmyocardial infarction model. J Cardiovasc Electrophysiol 30:741–746. https://doi.org/10.1111/jce.13912CrossRefPubMed

119.

Collaboration NCDRF (2017) Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 389:37–55. https://doi.org/10.1016/S0140-6736(16)31919-5CrossRef

120.

Esler M (2015) The sympathetic nervous system in hypertension: back to the future? Curr Hypertens Rep 17:11. https://doi.org/10.1007/s11906-014-0519-8CrossRefPubMed

121.

Grassi G (2009) Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54:690–697. https://doi.org/10.1161/HYPERTENSIONAHA.108.119883CrossRefPubMed

122.

Greenwood JP, Stoker JB, Mary DA (1999) Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation 100:1305–1310. https://doi.org/10.1161/01.cir.100.12.1305CrossRefPubMed

123.

Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108:560–565. https://doi.org/10.1161/01.CIR.0000081775.72651.B6CrossRefPubMed

124.

de Champlain J (1990) Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens Suppl 8:S77-85PubMed

125.

Esler MD, Hasking GJ, Willett IR, Leonard PW, Jennings GL (1985) Noradrenaline release and sympathetic nervous system activity. J Hypertens 3:117–129. https://doi.org/10.1097/00004872-198504000-00003CrossRefPubMed

126.

Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474–480. https://doi.org/10.1161/01.HYP.0000091371.53502.D3CrossRefPubMed

127.

Singh JP, Larson MG, Tsuji H, Evans JC, O’Donnell CJ, Levy D (1998) Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 32:293–297. https://doi.org/10.1161/01.hyp.32.2.293CrossRefPubMed

128.

Fisher JP, Paton JF (2012) The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 26:463–475. https://doi.org/10.1038/jhh.2011.66CrossRefPubMed

129.

Zucker IH, Schultz HD, Li YF, Wang Y, Wang W, Patel KP (2004) The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. Prog Biophys Mol Biol 84:217–232. https://doi.org/10.1016/j.pbiomolbio.2003.11.010CrossRefPubMed

130.

Larsen HE, Lefkimmiatis K, Paterson DJ (2016) Sympathetic neurons are a powerful driver of myocyte function in cardiovascular disease. Sci Rep 6:38898. https://doi.org/10.1038/srep38898CrossRefPubMedPubMedCentral

131.

Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ, Herring N (2013) Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 305:H980-986. https://doi.org/10.1152/ajpheart.00255.2013CrossRefPubMedPubMedCentral

132.

DiBona GF (2002) Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 11:197–200. https://doi.org/10.1097/00041552-200203000-00011CrossRefPubMed

133.

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281. https://doi.org/10.1016/S0140-6736(09)60566-3CrossRefPubMed

134.

Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934. https://doi.org/10.1056/NEJMc0904179CrossRefPubMed

135.

Li D, Lee CW, Buckler K, Parekh A, Herring N, Paterson DJ (2012) Abnormal intracellular calcium homeostasis in sympathetic neurons from young prehypertensive rats. Hypertension 59:642–649. https://doi.org/10.1161/HYPERTENSIONAHA.111.186460CrossRefPubMed

136.

Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, Haass M (2003) Increased cardiac norepinephrine release in spontaneously hypertensive rats: role of presynaptic alpha-2A adrenoceptors. J Hypertens 21:1363–1369. https://doi.org/10.1097/00004872-200307000-00026CrossRefPubMed

137.

Shanks J, Mane S, Ryan R, Paterson DJ (2013) Ganglion-specific impairment of the norepinephrine transporter in the hypertensive rat. Hypertension 61:187–193. https://doi.org/10.1161/HYPERTENSIONAHA.112.202184CrossRefPubMed

138.

Castellano M, Bohm M (1997) The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 29:715–722. https://doi.org/10.1161/01.hyp.29.3.715CrossRefPubMed

139.

Palatini P, Julius S (2009) The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep 11:199–205. https://doi.org/10.1007/s11906-009-0035-4CrossRefPubMed

140.

Bohm M, Kirchmayr R, Erdmann E (1995) Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc Res 30:611–618PubMed

141.

Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH (2006) How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24:2131–2141. https://doi.org/10.1097/01.hjh.0000249685.58370.28CrossRefPubMed

142.

Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12:451–459. https://doi.org/10.1016/s0895-7061(99)00005-9CrossRefPubMed

143.

Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid 23:209–213. https://doi.org/10.1080/13506129.2016.1257986CrossRefPubMed

144.

Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ (1985) Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6:737–743. https://doi.org/10.1016/s0735-1097(85)80475-7CrossRefPubMed

145.

Ikeda S, Yanagisawa N, Hongo M, Ito N (1987) Vagus nerve and celiac ganglion lesions in generalized amyloidosis. A correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 79:129–139. https://doi.org/10.1016/0022-510x(87)90267-xCrossRefPubMed

146.

Ikeda S-i (2022) Amyloid neuropathy and autonomic dysfunction. Neurol Clin Neurosci 10:137–146. https://doi.org/10.1111/ncn3.12601CrossRef

147.

Bernardi L, Passino C, Porta C, Anesi E, Palladini G, Merlini G (2002) Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 88:615–621. https://doi.org/10.1136/heart.88.6.615CrossRefPubMedPubMedCentral

148.

King P, Kates AM (2022) Management of cardiac symptoms in amyloidosis. Am J Med 135(Suppl 1):S9–S12. https://doi.org/10.1016/j.amjmed.2022.02.005CrossRefPubMed

149.

Gemmi F, Miliani A, Bergesio F, Salvadori M, Merlini G (1996) Functional study of autonomic neuropathy in primary (AL) amyloidosis. Amyloid 3:167–172. https://doi.org/10.3109/13506129609045517CrossRef

150.

Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ (2002) Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 23:157–161. https://doi.org/10.1053/euhj.2001.2972CrossRefPubMed

151.

Yamada S, Yoshihisa A, Hijioka N, Kamioka M, Kaneshiro T, Yokokawa T, Misaka T, Ishida T, Takeishi Y (2020) Autonomic dysfunction in cardiac amyloidosis assessed by heart rate variability and heart rate turbulence. Ann Noninvasive Electrocardiol 25:e12749. https://doi.org/10.1111/anec.12749CrossRefPubMedPubMedCentral

152.

Lamb YN (2021) Tafamidis: a review in transthyretin amyloid cardiomyopathy. Am J Cardiovasc Drugs 21:113–121. https://doi.org/10.1007/s40256-020-00461-7CrossRefPubMed

153.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689CrossRefPubMed

154.

Stern LK, Patel J (2022) Cardiac amyloidosis treatment. Methodist Debakey Cardiovasc J 18:59–72. https://doi.org/10.14797/mdcvj.1050CrossRefPubMedPubMedCentral

155.

Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, Hung RR, Slosky D, Stevenson WG, Michaud GF, John RM (2020) Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace 22:1216–1223. https://doi.org/10.1093/europace/euaa094CrossRefPubMed

156.

Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24:793–798. https://doi.org/10.1111/jce.12123CrossRefPubMed

157.

Akashi YJ, Nef HM, Lyon AR (2015) Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol 12:387–397. https://doi.org/10.1038/nrcardio.2015.39CrossRefPubMed

158.

Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology. Eur J Heart Fail 18:8–27. https://doi.org/10.1002/ejhf.424CrossRefPubMed

159.

Lyon AR, Citro R, Schneider B, Morel O, Ghadri JR, Templin C, Omerovic E (2021) Pathophysiology of Takotsubo syndrome: JACC state-of-the-art review. J Am Coll Cardiol 77:902–921. https://doi.org/10.1016/j.jacc.2020.10.060CrossRefPubMed

160.

Redfors B, Ali A, Shao Y, Lundgren J, Gan LM, Omerovic E (2014) Different catecholamines induce different patterns of Takotsubo-like cardiac dysfunction in an apparently afterload dependent manner. Int J Cardiol 174:330–336. https://doi.org/10.1016/j.ijcard.2014.04.103CrossRefPubMed

161.

Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC (2005) Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352:539–548. https://doi.org/10.1056/NEJMoa043046CrossRefPubMed

162.

Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Yh S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C (2018) International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 39:2032–2046. https://doi.org/10.1093/eurheartj/ehy076CrossRefPubMedPubMedCentral

163.

Martin EA, Prasad A, Rihal CS, Lerman LO, Lerman A (2010) Endothelial function and vascular response to mental stress are impaired in patients with apical ballooning syndrome. J Am Coll Cardiol 56:1840–1846. https://doi.org/10.1016/j.jacc.2010.03.107CrossRefPubMedPubMedCentral

164.

Redfors B, Shao Y, Ali A, Omerovic E (2014) Are ischemic stunning, conditioning, and “Takotsubo” different sides to the same coin? Int J Cardiol 172:490–491. https://doi.org/10.1016/j.ijcard.2014.01.052CrossRefPubMed

165.

Land S, Niederer SA, Louch WE, Roe AT, Aronsen JM, Stuckey DJ, Sikkel MB, Tranter MH, Lyon AR, Harding SE, Smith NP (2014) Computational modeling of Takotsubo cardiomyopathy: effect of spatially varying beta-adrenergic stimulation in the rat left ventricle. Am J Physiol Heart Circ Physiol 307:H1487-1496. https://doi.org/10.1152/ajpheart.00443.2014CrossRefPubMedPubMedCentral

166.

Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O’Gara P, Stuckey DJ, Nikolaev VO, Diakonov I, Pannell L, Gong H, Sun H, Peters NS, Petrou M, Zheng Z, Gorelik J, Lyon AR, Harding SE (2012) High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 126:697–706. https://doi.org/10.1161/CIRCULATIONAHA.112.111591CrossRefPubMedPubMedCentral

167.

Borchert T, Hubscher D, Guessoum CI, Lam TD, Ghadri JR, Schellinger IN, Tiburcy M, Liaw NY, Li Y, Haas J, Sossalla S, Huber MA, Cyganek L, Jacobshagen C, Dressel R, Raaz U, Nikolaev VO, Guan K, Thiele H, Meder B, Wollnik B, Zimmermann WH, Luscher TF, Hasenfuss G, Templin C, Streckfuss-Bomeke K (2017) Catecholamine-dependent beta-adrenergic signaling in a pluripotent stem cell model of Takotsubo cardiomyopathy. J Am Coll Cardiol 70:975–991. https://doi.org/10.1016/j.jacc.2017.06.061CrossRefPubMed

168.

Vaccaro A, Despas F, Delmas C, Lairez O, Lambert E, Lambert G, Labrunee M, Guiraud T, Esler M, Galinier M, Senard JM, Pathak A (2014) Direct evidences for sympathetic hyperactivity and baroreflex impairment in Tako Tsubo cardiopathy. PLoS ONE 9:e93278. https://doi.org/10.1371/journal.pone.0093278CrossRefPubMedPubMedCentral

169.

Akashi YJ, Barbaro G, Sakurai T, Nakazawa K, Miyake F (2007) Cardiac autonomic imbalance in patients with reversible ventricular dysfunction Takotsubo cardiomyopathy. QJM 100:335–343. https://doi.org/10.1093/qjmed/hcm028CrossRefPubMed

170.

Ortak J, Khattab K, Barantke M, Wiegand UK, Bansch D, Ince H, Nienaber CA, Bonnemeier H (2009) Evolution of cardiac autonomic nervous activity indices in patients presenting with transient left ventricular apical ballooning. Pacing Clin Electrophysiol 32(Suppl 1):S21-25. https://doi.org/10.1111/j.1540-8159.2008.02221.xCrossRefPubMed

171.

Redfors B, Vedad R, Angeras O, Ramunddal T, Petursson P, Haraldsson I, Ali A, Dworeck C, Odenstedt J, Ioaness D, Libungan B, Shao Y, Albertsson P, Stone GW, Omerovic E (2015) Mortality in Takotsubo syndrome is similar to mortality in myocardial infarction—a report from the SWEDEHEART registry. Int J Cardiol 185:282–289. https://doi.org/10.1016/j.ijcard.2015.03.162CrossRefPubMed

172.

Stiermaier T, Moeller C, Oehler K, Desch S, Graf T, Eitel C, Vonthein R, Schuler G, Thiele H, Eitel I (2016) Long-term excess mortality in Takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail 18:650–656. https://doi.org/10.1002/ejhf.494CrossRefPubMed

173.

Norcliffe-Kaufmann L, Kaufmann H, Martinez J, Katz SD, Tully L, Reynolds HR (2016) Autonomic findings in Takotsubo cardiomyopathy. Am J Cardiol 117:206–213. https://doi.org/10.1016/j.amjcard.2015.10.028CrossRefPubMed

174.

Medina de Chazal H, Del Buono MG, Keyser-Marcus L, Ma L, Moeller FG, Berrocal D, Abbate A (2018) Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review. J Am Coll Cardiol 72:1955–1971. https://doi.org/10.1016/j.jacc.2018.07.072CrossRefPubMed

175.

Santoro F, Ieva R, Musaico F, Ferraretti A, Triggiani G, Tarantino N, Di Biase M, Brunetti ND (2014) Lack of efficacy of drug therapy in preventing Takotsubo cardiomyopathy recurrence: a meta-analysis. Clin Cardiol 37:434–439. https://doi.org/10.1002/clc.22280CrossRefPubMedPubMedCentral

176.

Singh K, Carson K, Usmani Z, Sawhney G, Shah R, Horowitz J (2014) Systematic review and meta-analysis of incidence and correlates of recurrence of Takotsubo cardiomyopathy. Int J Cardiol 174:696–701. https://doi.org/10.1016/j.ijcard.2014.04.221CrossRefPubMed

177.

Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938. https://doi.org/10.1056/NEJMoa1406761CrossRefPubMed

178.

Ackerman MJ, Clapham DE (1997) Ion channels—basic science and clinical disease. N Engl J Med 336:1575–1586. https://doi.org/10.1056/NEJM199705293362207CrossRefPubMed

179.

Keating MT, Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104:569–580. https://doi.org/10.1016/s0092-8674(01)00243-4CrossRefPubMed

180.

Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E (1985) The long QT syndrome: a prospective international study. Circulation 71:17–21. https://doi.org/10.1161/01.cir.71.1.17CrossRefPubMed

181.

Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S (2005) Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 294:2975–2980. https://doi.org/10.1001/jama.294.23.2975CrossRefPubMed

182.

Schwartz PJ (2001) Another role for the sympathetic nervous system in the long QT syndrome? J Cardiovasc Electrophysiol 12:500–502. https://doi.org/10.1046/j.1540-8167.2001.00500.xCrossRefPubMed

183.

Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, Vincent GM, Benhorin J, Heilbron EL, Towbin JA, Priori SG, Napolitano C, Zhang L, Medina A, Andrews ML, Timothy K (1999) Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 84:876–879. https://doi.org/10.1016/s0002-9149(99)00458-0CrossRefPubMed

184.

Saadeh K, Shivkumar K, Jeevaratnam K (2020) Targeting the beta-adrenergic receptor in the clinical management of congenital long QT syndrome. Ann N Y Acad Sci 1474:27–46. https://doi.org/10.1111/nyas.14425CrossRefPubMed

185.

Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Horie M, Napolitano C, Towbin JA, Priori SG, Shimizu W (2002) Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 23:975–983. https://doi.org/10.1053/euhj.2001.3079CrossRefPubMed

186.

Shimizu W, Antzelevitch C (2000) Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35:778–786. https://doi.org/10.1016/s0735-1097(99)00582-3CrossRefPubMed

187.

Shimizu W, Noda T, Takaki H, Kurita T, Nagaya N, Satomi K, Suyama K, Aihara N, Kamakura S, Sunagawa K, Echigo S, Nakamura K, Ohe T, Towbin JA, Napolitano C, Priori SG (2003) Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 41:633–642. https://doi.org/10.1016/s0735-1097(02)02850-4CrossRefPubMed

188.

Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L (1999) Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 34:823–829. https://doi.org/10.1016/s0735-1097(99)00255-7CrossRefPubMed

189.

Takenaka K, Ai T, Shimizu W, Kobori A, Ninomiya T, Otani H, Kubota T, Takaki H, Kamakura S, Horie M (2003) Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 107:838–844. https://doi.org/10.1161/01.cir.0000048142.85076.a2CrossRefPubMed

190.

Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB (2002) Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 77:413–421. https://doi.org/10.4065/77.5.413CrossRefPubMed

191.

Tanabe Y, Inagaki M, Kurita T, Nagaya N, Taguchi A, Suyama K, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Towbin JA, Priori SG, Shimizu W (2001) Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 37:911–919. https://doi.org/10.1016/s0735-1097(00)01200-6CrossRefPubMed

192.

Rizzo S, Basso C, Troost D, Aronica E, Frigo AC, Driessen AH, Thiene G, Wilde AA, van der Wal AC (2014) T-cell-mediated inflammatory activity in the stellate ganglia of patients with ion-channel disease and severe ventricular arrhythmias. Circ Arrhythm Electrophysiol 7:224–229. https://doi.org/10.1161/CIRCEP.113.001184CrossRefPubMed

193.

Kies P, Paul M, Gerss J, Stegger L, Monnig G, Schober O, Wichter T, Schafers M, Schulze-Bahr E (2011) Impaired cardiac sympathetic innervation in symptomatic patients with long QT syndrome. Eur J Nucl Med Mol Imaging 38:1899–1907. https://doi.org/10.1007/s00259-011-1852-7CrossRefPubMed

194.

Muller KD, Jakob H, Neuzner J, Grebe SF, Schlepper M, Pitschner HF (1993) 123I-metaiodobenzylguanidine scintigraphy in the detection of irregular regional sympathetic innervation in long QT syndrome. Eur Heart J 14:316–325. https://doi.org/10.1093/eurheartj/14.3.316CrossRefPubMed

195.

Ahn J, Kim HJ, Choi JI, Lee KN, Shim J, Ahn HS, Kim YH (2017) Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS ONE 12:e0185680. https://doi.org/10.1371/journal.pone.0185680CrossRefPubMedPubMedCentral

196.

Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S, Miyamoto Y, Goldenberg I, Andrews ML, McNitt S (2007) Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 115:2481–2489. https://doi.org/10.1161/CIRCULATIONAHA.106.665406CrossRefPubMedPubMedCentral

197.

Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML (2000) Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101:616–623. https://doi.org/10.1161/01.cir.101.6.616CrossRefPubMed

198.

Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J (2004) Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292:1341–1344. https://doi.org/10.1001/jama.292.11.1341CrossRefPubMed

199.

Schwartz PJ, Ackerman MJ, Antzelevitch C, Bezzina CR, Borggrefe M, Cuneo BF, Wilde AAM (2020) Inherited cardiac arrhythmias. Nat Rev Dis Primers 6:58. https://doi.org/10.1038/s41572-020-0188-7CrossRefPubMedPubMedCentral

200.

Shimizu W, Moss AJ, Wilde AA, Towbin JA, Ackerman MJ, January CT, Tester DJ, Zareba W, Robinson JL, Qi M, Vincent GM, Kaufman ES, Hofman N, Noda T, Kamakura S, Miyamoto Y, Shah S, Amin V, Goldenberg I, Andrews ML, McNitt S (2009) Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol 54:2052–2062. https://doi.org/10.1016/j.jacc.2009.08.028CrossRefPubMedPubMedCentral

201.

De Ferrari GM, Locati EH, Priori SG, Schwartz PJ (1995) Left cardiac sympathetic denervation in long QT syndrome patients. J Interv Cardiol 8:776–781. https://doi.org/10.1111/j.1540-8183.1995.tb00930.xCrossRefPubMed

202.

Dusi V, De Ferrari GM, Pugliese L, Schwartz PJ (2019) Cardiac sympathetic denervation in channelopathies. Front Cardiovasc Med 6:27. https://doi.org/10.3389/fcvm.2019.00027CrossRefPubMedPubMedCentral

203.

Dusi V, Pugliese L, De Ferrari GM, Odero A, Crotti L, Dagradi F, Castelletti S, Vicentini A, Rordorf R, Li C, Shkolnikova M, Spazzolini C, Schwartz PJ (2022) Left cardiac sympathetic denervation for long QT syndrome: 50 years’ experience provides guidance for management. JACC Clin Electrophysiol 8:281–294. https://doi.org/10.1016/j.jacep.2021.09.002CrossRefPubMed

204.

Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U (1991) Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation 84:503–511. https://doi.org/10.1161/01.cir.84.2.503CrossRefPubMed

205.

Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D (2004) Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 109:1826–1833. https://doi.org/10.1161/01.CIR.0000125523.14403.1ECrossRefPubMed

206.

Cerrone M, Napolitano C, Priori SG (2009) Catecholaminergic polymorphic ventricular tachycardia: a paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. Heart Rhythm 6:1652–1659. https://doi.org/10.1016/j.hrthm.2009.06.033CrossRefPubMed

207.

Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384. https://doi.org/10.1086/324565CrossRefPubMedPubMedCentral

208.

Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196–200. https://doi.org/10.1161/01.cir.103.2.196CrossRefPubMed

209.

Wehrens XH (2007) The molecular basis of catecholaminergic polymorphic ventricular tachycardia: what are the different hypotheses regarding mechanisms? Heart Rhythm 4:794–797. https://doi.org/10.1016/j.hrthm.2006.12.016CrossRefPubMed

210.

Jiang D, Wang R, Xiao B, Kong H, Hunt DJ, Choi P, Zhang L, Chen SR (2005) Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 97:1173–1181. https://doi.org/10.1161/01.RES.0000192146.85173.4bCrossRefPubMed

211.

Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, Landry DW, Kontula K, Swan H, Marks AR (2004) Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 109:3208–3214. https://doi.org/10.1161/01.CIR.0000132472.98675.ECCrossRefPubMed

212.

Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG (2006) Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 99:292–298. https://doi.org/10.1161/01.RES.0000235869.50747.e1CrossRefPubMed

213.

De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, Crotti L, Davis AM, Eldar M, Kharlap M, Khoury A, Krahn AD, Leenhardt A, Moir CR, Odero A, Olde Nordkamp L, Paul T, Roses INF, Shkolnikova M, Till J, Wilde AA, Ackerman MJ, Schwartz PJ (2015) Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 131:2185–2193. https://doi.org/10.1161/CIRCULATIONAHA.115.015731CrossRefPubMed

214.

Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A (2009) Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119:2426–2434. https://doi.org/10.1161/CIRCULATIONAHA.108.829267CrossRefPubMed

215.

Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, Triedman J, Van Hare GF, Gold MR (2017) Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent? Heart Rhythm 14:e41–e44. https://doi.org/10.1016/j.hrthm.2016.09.012CrossRefPubMed

216.

van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA (2011) Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57:2244–2254. https://doi.org/10.1016/j.jacc.2011.01.026CrossRefPubMedPubMedCentral

217.

Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG (2011) Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109:291–295. https://doi.org/10.1161/CIRCRESAHA.111.247338CrossRefPubMed

218.

Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC (2009) Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15:380–383. https://doi.org/10.1038/nm.1942CrossRefPubMedPubMedCentral

219.

Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, Batra AS, Kaufman ES, Fairbrother DL, Saarel EV, Etheridge SP, Kanter RJ, Carboni MP, Dzurik MV, Fountain D, Chen H, Ely EW, Roden DM, Knollmann BC (2017) Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol 2:759–766. https://doi.org/10.1001/jamacardio.2017.1320CrossRefPubMedPubMedCentral

220.

Collura CA, Johnson JN, Moir C, Ackerman MJ (2009) Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 6:752–759. https://doi.org/10.1016/j.hrthm.2009.03.024CrossRefPubMed

221.

Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ (2008) Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 358:2024–2029. https://doi.org/10.1056/NEJMoa0708006CrossRefPubMed

222.

Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823. https://doi.org/10.1056/NEJM198409273111303CrossRefPubMed

223.

Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, Brown MR (1989) Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86:43–48. https://doi.org/10.1016/0002-9343(89)90228-3CrossRefPubMed

224.

Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043–1065CrossRef

225.

Shaffer F, Ginsberg JP (2017) An overview of heart rate variability metrics and norms. Front Public Health 5:258. https://doi.org/10.3389/fpubh.2017.00258CrossRefPubMedPubMedCentral

226.

Fei L, Copie X, Malik M, Camm AJ (1996) Short- and long-term assessment of heart rate variability for risk stratification after acute myocardial infarction. Am J Cardiol 77:681–684. https://doi.org/10.1016/s0002-9149(97)89199-0CrossRefPubMed

227.

Kleiger RE, Stein PK, Bigger JT Jr (2005) Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 10:88–101. https://doi.org/10.1111/j.1542-474X.2005.10101.xCrossRefPubMedPubMedCentral

228.

Jiang W, Hathaway WR, McNulty S, Larsen RL, Hansley KL, Zhang Y, O’Connor CM (1997) Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. Am J Cardiol 80:808–811. https://doi.org/10.1016/s0002-9149(97)00526-2CrossRefPubMed

229.

Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA (1998) Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98:1510–1516. https://doi.org/10.1161/01.cir.98.15.1510CrossRefPubMed

230.

Shaffer F, McCraty R, Zerr CL (2014) A healthy heart is not a metronome: an integrative review of the heart’s anatomy and heart rate variability. Front Psychol 5:1040. https://doi.org/10.3389/fpsyg.2014.01040CrossRefPubMedPubMedCentral

231.

Hadase M, Azuma A, Zen K, Asada S, Kawasaki T, Kamitani T, Kawasaki S, Sugihara H, Matsubara H (2004) Very low frequency power of heart rate variability is a powerful predictor of clinical prognosis in patients with congestive heart failure. Circ J 68:343–347. https://doi.org/10.1253/circj.68.343CrossRefPubMed

232.

Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D (1994) Reduced heart rate variability and mortality risk in an elderly cohort the Framingham heart study. Circulation 90:878–883. https://doi.org/10.1161/01.cir.90.2.878CrossRefPubMed

233.

Kember GC, Fenton GA, Armour JA, Kalyaniwalla N (2001) Competition model for aperiodic stochastic resonance in a Fitzhugh-Nagumo model of cardiac sensory neurons. Phys Rev E Stat Nonlin Soft Matter Phys 63:041911. https://doi.org/10.1103/PhysRevE.63.041911CrossRefPubMed

234.

Kember GC, Fenton GA, Collier K, Armour JA (2000) Aperiodic stochastic resonance in a hysteretic population of cardiac neurons. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics 61:1816–1824. https://doi.org/10.1103/physreve.61.1816CrossRefPubMed

235.

Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213:220–222. https://doi.org/10.1126/science.6166045CrossRefPubMed

236.

McCraty R, Shaffer F (2015) Heart rate variability: new perspectives on physiological mechanisms, assessment of self-regulatory capacity, and health risk. Glob Adv Health Med 4:46–61. https://doi.org/10.7453/gahmj.2014.073CrossRefPubMedPubMedCentral

237.

Grossman P, Taylor EW (2007) Toward understanding respiratory sinus arrhythmia: relations to cardiac vagal tone, evolution and biobehavioral functions. Biol Psychol 74:263–285. https://doi.org/10.1016/j.biopsycho.2005.11.014CrossRefPubMed

238.

Billman GE (2013) The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. Front Physiol 4:26. https://doi.org/10.3389/fphys.2013.00026CrossRefPubMedPubMedCentral

239.

Wehrwein EA, Joyner MJ (2013) Regulation of blood pressure by the arterial baroreflex and autonomic nervous system. Handb Clin Neurol 117:89–102. https://doi.org/10.1016/B978-0-444-53491-0.00008-0CrossRefPubMed

240.

Chapleau MW, Li Z, Meyrelles SS, Ma X, Abboud FM (2001) Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Ann N Y Acad Sci 940:1–19. https://doi.org/10.1111/j.1749-6632.2001.tb03662.xCrossRefPubMed

241.

La Rovere MT, Pinna GD, Raczak G (2008) Baroreflex sensitivity: measurement and clinical implications. Ann Noninvasive Electrocardiol 13:191–207. https://doi.org/10.1111/j.1542-474X.2008.00219.xCrossRefPubMedPubMedCentral

242.

La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ (1998) Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone And Reflexes After Myocardial Infarction) Investigators. Lancet 351:478–484. https://doi.org/10.1016/s0140-6736(97)11144-8CrossRefPubMed

243.

Lanfranchi PA, Somers VK (2002) Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol 283:R815-826. https://doi.org/10.1152/ajpregu.00051.2002CrossRefPubMed

244.

Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, Pozzoli M, Opasich C, Tavazzi L (1997) Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 96:3450–3458. https://doi.org/10.1161/01.cir.96.10.3450CrossRefPubMed

245.

Pinna GD, Maestri R, Capomolla S, Febo O, Robbi E, Cobelli F, La Rovere MT (2005) Applicability and clinical relevance of the transfer function method in the assessment of baroreflex sensitivity in heart failure patients. J Am Coll Cardiol 46:1314–1321. https://doi.org/10.1016/j.jacc.2005.06.062CrossRefPubMed

246.

Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, Camm AJ, Bigger JT Jr, Schomig A (1999) Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 353:1390–1396. https://doi.org/10.1016/S0140-6736(98)08428-1CrossRefPubMed

247.

Huikuri HV, Exner DV, Kavanagh KM, Aggarwal SG, Mitchell LB, Messier MD, Becker D, Sheldon RS, Bloch Thomsen PE, Carisma IR (2010) Attenuated recovery of heart rate turbulence early after myocardial infarction identifies patients at high risk for fatal or near-fatal arrhythmic events. Heart Rhythm 7:229–235. https://doi.org/10.1016/j.hrthm.2009.11.004CrossRefPubMed

248.

Koyama J, Watanabe J, Yamada A, Koseki Y, Konno Y, Toda S, Shinozaki T, Miura M, Fukuchi M, Ninomiya M, Kagaya Y, Shirato K (2002) Evaluation of heart-rate turbulence as a new prognostic marker in patients with chronic heart failure. Circ J 66:902–907. https://doi.org/10.1253/circj.66.902CrossRefPubMed

249.

Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, Wu JL (1984) Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 27:149–155. https://doi.org/10.1021/jm00368a008CrossRefPubMed

250.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, Investigators A-H (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212–2221. https://doi.org/10.1016/j.jacc.2010.01.014CrossRefPubMed

251.

Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D et al (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477PubMed

252.

Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, Tsuchihashi K, Shimamoto K (1998) Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 5:579–590. https://doi.org/10.1016/s1071-3581(98)90112-xCrossRefPubMed

253.

Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M (1988) Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252–1258. https://doi.org/10.1016/0735-1097(88)92608-3CrossRefPubMed

254.

Asghar O, Arumugam P, Armstrong I, Ray S, Schmitt M, Malik RA (2017) Iodine-123 metaiodobenzylguanidine scintigraphy for the assessment of cardiac sympathetic innervation and the relationship with cardiac autonomic function in healthy adults using standardized methods. Nucl Med Commun 38:44–50. https://doi.org/10.1097/MNM.0000000000000608CrossRefPubMedPubMedCentral

255.

Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA, Canty JM Jr, Fallavollita JA (2005) Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 46:1368–1374PubMed

256.

Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, American College of C, American Heart A, Canadian Cardiovascular S (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:671–719. https://doi.org/10.1016/j.jacc.2004.07.002CrossRefPubMed

257.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757–1780. https://doi.org/10.1016/j.jacc.2021.12.011CrossRefPubMed

258.

CIBIS Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRef

259.

MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007CrossRef

260.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 334:1349–1355. https://doi.org/10.1056/NEJM199605233342101CrossRefPubMed

261.

Vanhoutte PM, Gao Y (2013) Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 13:265–273. https://doi.org/10.1016/j.coph.2012.12.002CrossRefPubMed

262.

Jaillon P (1990) Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol 66:21C-23C. https://doi.org/10.1016/0002-9149(90)90758-sCrossRefPubMed

263.

McAinsh J, Cruickshank JM (1990) Beta-blockers and central nervous system side effects. Pharmacol Ther 46:163–197. https://doi.org/10.1016/0163-7258(90)90092-gCrossRefPubMed

264.

Zimmerman BG (1981) Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci (Lond) 60:343–348. https://doi.org/10.1042/cs0600343CrossRefPubMed

265.

Peach MJ, Bumpus FM, Khairallah PA (1969) Inhibition of norepinephrine uptake in hearts by angiotensin II and analogs. J Pharmacol Exp Ther 167:291–299PubMed

266.

Huber G, Schuster F, Raasch W (2017) Brain renin-angiotensin system in the pathophysiology of cardiovascular diseases. Pharmacol Res 125:72–90. https://doi.org/10.1016/j.phrs.2017.06.016CrossRefPubMed

267.

Reid IA (1992) Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 262:E763-778. https://doi.org/10.1152/ajpendo.1992.262.6.E763CrossRefPubMed

268.

Shi Z, Chen AD, Xu Y, Chen Q, Gao XY, Wang W, Zhu GQ (2009) Long-term administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pflugers Arch 458:247–257. https://doi.org/10.1007/s00424-008-0627-xCrossRefPubMed

269.

Wang HJ, Zhang F, Zhang Y, Gao XY, Wang W, Zhu GQ (2005) AT1 receptor in paraventricular nucleus mediates the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. Auton Neurosci 121:56–63. https://doi.org/10.1016/j.autneu.2005.07.003CrossRefPubMed

270.

Ma R, Schultz HD, Wang W (1999) Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs. Am J Physiol 277:H15-22. https://doi.org/10.1152/ajpheart.1999.277.1.H15CrossRefPubMed

271.

De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV (2003) Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 146:E17. https://doi.org/10.1016/S0002-8703(03)00366-1CrossRefPubMed

272.

Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G (1997) Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 96:1173–1179. https://doi.org/10.1161/01.cir.96.4.1173CrossRefPubMed

273.

Hikosaka M, Yuasa F, Yuyama R, Mimura J, Kawamura A, Motohiro M, Iwasaki M, Sugiura T, Iwasaka T (2002) Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. J Cardiovasc Pharmacol 40:875–880. https://doi.org/10.1097/00005344-200212000-00008CrossRefPubMed

274.

Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H (1997) ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38:1085–1089PubMed

275.

Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail 9:e002744. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744CrossRefPubMed

276.

Boehmer AA, Schubert T, von Stuelpnagel L, Bauer A, Dobre B, Kaess BM, Ehrlich JR (2022) Abstract 13303: influence of ARNI on cardiac autonomic nervous system. Circulation 146:A13303CrossRef

277.

Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP (2017) Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 35:2059–2068. https://doi.org/10.1097/HJH.0000000000001434CrossRefPubMed

278.

Wan N, Rahman A, Hitomi H, Nishiyama A (2018) The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne) 9:421. https://doi.org/10.3389/fendo.2018.00421CrossRefPubMed

279.

Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J, investigators Et (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19:148. https://doi.org/10.1186/s12933-020-01127-zCrossRefPubMedPubMedCentral

280.

Cha YM, Oh J, Miyazaki C, Hayes DL, Rea RF, Shen WK, Asirvatham SJ, Kemp BJ, Hodge DO, Chen PS, Chareonthaitawee P (2008) Cardiac resynchronization therapy upregulates cardiac autonomic control. J Cardiovasc Electrophysiol 19:1045–1052. https://doi.org/10.1111/j.1540-8167.2008.01190.xCrossRefPubMedPubMedCentral

281.

Alvarez CK, Cronin E, Baker WL, Kluger J (2019) Heart failure as a substrate and trigger for ventricular tachycardia. J Interv Card Electrophysiol 56:229–247. https://doi.org/10.1007/s10840-019-00623-xCrossRefPubMed

282.

Fantoni C, Raffa S, Regoli F, Giraldi F, La Rovere MT, Prentice J, Pastori F, Fratini S, Salerno-Uriarte JA, Klein HU, Auricchio A (2005) Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 46:1875–1882. https://doi.org/10.1016/j.jacc.2005.06.081CrossRefPubMed

283.

Sarzi Braga S, La Rovere MT, Pedretti RF (2006) Baroreflex sensitivity normalization after cardiac resynchronization therapy. Int J Cardiol 109:118–120. https://doi.org/10.1016/j.ijcard.2005.03.072CrossRefPubMed

284.

Sredniawa B, Lenarczyk R, Musialik-Lydka A, Kowalski O, Kowalczyk J, Cebula S, Sliwinska A, Szulik M, Kalarus Z (2009) Effects of cardiac resynchronization therapy on heart rate turbulence. Pacing Clin Electrophysiol 32(Suppl 1):S90-93. https://doi.org/10.1111/j.1540-8159.2008.02260.xCrossRefPubMed

285.

Irie T, Yamakawa K, Hamon D, Nakamura K, Shivkumar K, Vaseghi M (2017) Cardiac sympathetic innervation via middle cervical and stellate ganglia and antiarrhythmic mechanism of bilateral stellectomy. Am J Physiol Heart Circ Physiol 312:392–405. https://doi.org/10.1152/ajpheart.00644.2016CrossRef

286.

Schwartz PJ, Stone HL (1980) Left stellectomy in the prevention of ventricular fibrillation caused by acute myocardial ischemia in conscious dogs with anterior myocardial infarction. Circulation 62:1256–1265. https://doi.org/10.1161/01.cir.62.6.1256CrossRefPubMed

287.

Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, Sorg JM, Gima J, Mandal K, Saenz Morales LC, Lokhandwala Y, Shivkumar K (2017) Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol 69:3070–3080. https://doi.org/10.1016/j.jacc.2017.04.035CrossRefPubMedPubMedCentral

288.

Dusi V, Gornbein J, Do DH, Sorg JM, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JS, Buch E, Fujimura OA, Boyle NG, Yanagawa J, Lee JM, Shivkumar K, Vaseghi M (2021) Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation. J Am Heart Assoc 10:e018371. https://doi.org/10.1161/JAHA.120.018371CrossRefPubMedPubMedCentral

289.

Conceicao-Souza GE, Pego-Fernandes PM, Cruz F, Guimaraes GV, Bacal F, Vieira ML, Grupi CJ, Giorgi MC, Consolim-Colombo FM, Negrao CE, Rondon MU, Moreira LF, Bocchi EA (2012) Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study. Eur J Heart Fail 14:1366–1373. https://doi.org/10.1093/eurjhf/hfs132CrossRefPubMed

290.

Vaseghi M, Gima J, Kanaan C, Ajijola OA, Marmureanu A, Mahajan A, Shivkumar K (2014) Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm 11:360–366. https://doi.org/10.1016/j.hrthm.2013.11.028CrossRefPubMed

291.

Waddell-Smith KE, Ertresvaag KN, Li J, Chaudhuri K, Crawford JR, Hamill JK, Haydock D, Skinner JR, Cardiac Inherited Disease Group New Z (2015) Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 8:1151–1158. https://doi.org/10.1161/CIRCEP.115.003159CrossRefPubMed

292.

Cha YM, Li X, Yang M, Han J, Wu G, Kapa SC, McLeod CJ, Noseworthy PA, Mulpuru SK, Asirvatham SJ, Brady PA, Rho RH, Friedman PA, Lee HC, Tian Y, Zhou S, Munger TM, Ackerman MJ, Shen WK (2019) Stellate ganglion block and cardiac sympathetic denervation in patients with inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 30:2920–2928. https://doi.org/10.1111/jce.14233CrossRefPubMedPubMedCentral

293.

Sanghai S, Abbott NJ, Dewland TA, Henrikson CA, Elman MR, Wollenberg M, Ivie R, Gonzalez-Sotomayor J, Nazer B (2021) Stellate Ganglion blockade with continuous infusion versus single injection for treatment of ventricular arrhythmia storm. JACC Clin Electrophysiol 7:452–460. https://doi.org/10.1016/j.jacep.2020.09.032CrossRefPubMed

294.

Fudim M, Qadri YJ, Waldron NH, Boortz-Marx RL, Ganesh A, Patel CB, Podgoreanu MV, Sun AY, Milano CA, Tong BC, Harpole DH Jr, Mathew JP, Piccini JP (2020) Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias. JACC Clin Electrophysiol 6:562–571. https://doi.org/10.1016/j.jacep.2019.12.017CrossRefPubMed

295.

Wittwer ED, Radosevich MA, Ritter M, Cha YM (2020) Stellate ganglion blockade for refractory ventricular arrhythmias: implications of ultrasound-guided technique and review of the evidence. J Cardiothorac Vasc Anesth 34:2245–2252. https://doi.org/10.1053/j.jvca.2019.12.015CrossRefPubMed

296.

Basantwani S, Shinde SR, Tendolkar B (2019) Management of ventricular storm with thoracic epidural anesthesia. Ann Card Anaesth 22:439–441. https://doi.org/10.4103/aca.ACA_98_18CrossRefPubMedPubMedCentral

297.

Do DH, Bradfield J, Ajijola OA, Vaseghi M, Le J, Rahman S, Mahajan A, Nogami A, Boyle NG, Shivkumar K (2017) Thoracic epidural anesthesia can be effective for the short-term management of ventricular tachycardia storm. J Am Heart Assoc 6:e007080. https://doi.org/10.1161/JAHA.117.007080CrossRefPubMedPubMedCentral

298.

Howard-Quijano K, Takamiya T, Dale EA, Yamakawa K, Zhou W, Buckley U, Mahajan A (2017) Effect of thoracic epidural anesthesia on ventricular excitability in a porcine model. Anesthesiology 126:1096–1106. https://doi.org/10.1097/ALN.0000000000001613CrossRefPubMed

299.

Bourke T, Vaseghi M, Michowitz Y, Sankhla V, Shah M, Swapna N, Boyle NG, Mahajan A, Narasimhan C, Lokhandwala Y, Shivkumar K (2010) Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation 121:2255–2262. https://doi.org/10.1161/CIRCULATIONAHA.109.929703CrossRefPubMedPubMedCentral

300.

Fujisawa Y, Nagai Y, Lei B, Nakano D, Fukui T, Hitomi H, Mori H, Masaki T, Nishiyama A (2011) Roles of central renin-angiotensin system and afferent renal nerve in the control of systemic hemodynamics in rats. Hypertens Res 34:1228–1232. https://doi.org/10.1038/hr.2011.115CrossRefPubMed

301.

Zhou H, Li Y, Xu Y, Liu H, Lai Y, Tan K, Liu X, Ou Z, Chen W, Du H, Liu Z, Yin Y (2022) Mapping renal innervations by renal nerve stimulation and characterizations of blood pressure response patterns. J Cardiovasc Transl Res 15:29–37. https://doi.org/10.1007/s12265-021-10149-1CrossRefPubMed

302.

Symplicity HTNI (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57:911–917. https://doi.org/10.1161/HYPERTENSIONAHA.110.163014CrossRef

303.

Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909. https://doi.org/10.1016/S0140-6736(10)62039-9CrossRef

304.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401. https://doi.org/10.1056/NEJMoa1402670CrossRefPubMed

305.

Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D’Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, Investigators SH-OMP (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451. https://doi.org/10.1016/S0140-6736(20)30554-7CrossRefPubMed

306.

Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, Investigators SH-OMT (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6CrossRefPubMed

307.

Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Bohm M (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390:2160–2170. https://doi.org/10.1016/S0140-6736(17)32281-XCrossRefPubMed

308.

de Jong MR, Adiyaman A, Gal P, Smit JJ, Delnoy PP, Heeg JE, van Hasselt BA, Lau EO, Persu A, Staessen JA, Ramdat Misier AR, Steinberg JS, Elvan A (2016) Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 68:707–714. https://doi.org/10.1161/HYPERTENSIONAHA.116.07492CrossRefPubMed

309.

Hoogerwaard AF, Adiyaman A, de Jong MR, Smit JJ, Heeg JE, van Hasselt B, Elvan A (2021) Renal nerve stimulation: complete versus incomplete renal sympathetic denervation. Blood Press 30:376–385. https://doi.org/10.1080/08037051.2021.1982376CrossRefPubMed

310.

Hawson J, Harmer JA, Cowan M, Virk S, Campbell T, Bennett RG, Anderson RD, Kalman J, Lee G, Kumar S (2021) Renal denervation for the management of refractory ventricular arrhythmias: a systematic review. JACC Clin Electrophysiol 7:100–108. https://doi.org/10.1016/j.jacep.2020.07.019CrossRefPubMed

311.

Zhang WH, Zhou QN, Lu YM, Li YD, Zhang L, Zhang JH, Xing Q, Lv WK, Cheng XC, Zhang GG, Wang XS, Gu Q, Lou X, Guli B, Tang BP, Zhou XH (2018) Renal denervation reduced ventricular arrhythmia after myocardial infarction by inhibiting sympathetic activity and remodeling. J Am Heart Assoc 7:e009938. https://doi.org/10.1161/JAHA.118.009938CrossRefPubMedPubMedCentral

312.

Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA, Kieval RS (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4:65–70. https://doi.org/10.1161/CIRCHEARTFAILURE.110.955013CrossRefPubMed

313.

Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing MA (2007) Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 50:904–910. https://doi.org/10.1161/HYPERTENSIONAHA.107.095216CrossRefPubMed

314.

Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC (2015) Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 3:487–496. https://doi.org/10.1016/j.jchf.2015.02.006CrossRefPubMed

315.

Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA (2011) Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 58:765–773. https://doi.org/10.1016/j.jacc.2011.06.008CrossRefPubMed

316.

Gronda E, Seravalle G, Trevano FQ, Costantino G, Casini A, Alsheraei A, Lovett EG, Vanoli E, Mancia G, Grassi G (2015) Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens 33:1704–1708. https://doi.org/10.1097/HJH.0000000000000603CrossRefPubMed

317.

Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT (2020) Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 76:1–13. https://doi.org/10.1016/j.jacc.2020.05.015CrossRefPubMed

318.

de Leeuw PW, Alnima T, Lovett E, Sica D, Bisognano J, Haller H, Kroon AA (2015) Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 65:187–192. https://doi.org/10.1161/HYPERTENSIONAHA.114.04492CrossRefPubMed

319.

Hamann JJ, Ruble SB, Stolen C, Wang M, Gupta RC, Rastogi S, Sabbah HN (2013) Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. Eur J Heart Fail 15:1319–1326. https://doi.org/10.1093/eurjhf/hft118CrossRefPubMedPubMedCentral

320.

Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109:120–124. https://doi.org/10.1161/01.CIR.0000105721.71640.DACrossRefPubMed

321.

Sabbah HN, Ilsar I, Zaretsky A, Rastogi S, Wang M, Gupta RC (2011) Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 16:171–178. https://doi.org/10.1007/s10741-010-9209-zCrossRefPubMedPubMedCentral

322.

Premchand RK, Sharma K, Mittal S, Monteiro R, Dixit S, Libbus I, DiCarlo LA, Ardell JL, Rector TS, Amurthur B, KenKnight BH, Anand IS (2014) Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail 20:808–816. https://doi.org/10.1016/j.cardfail.2014.08.009CrossRefPubMed

323.

Schwartz PJ, De Ferrari GM (2009) Vagal stimulation for heart failure: background and first in-man study. Heart Rhythm 6:S76-81. https://doi.org/10.1016/j.hrthm.2009.08.012CrossRefPubMed

324.

Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, Starling RC, Mann DL (2016) Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF trial. J Am Coll Cardiol 68:149–158. https://doi.org/10.1016/j.jacc.2016.03.525CrossRefPubMed

325.

Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D’Onofrio A, Solomon SD, Wold N, Ruble SB (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36:425–433. https://doi.org/10.1093/eurheartj/ehu345CrossRefPubMed

326.

Anand IS, Konstam MA, Klein HU, Mann DL, Ardell JL, Gregory DD, Massaro JM, Libbus I, DiCarlo LA, Udelson JJE, Butler J, Parker JD, Teerlink JR (2020) Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. ESC Heart Fail 7:75–83. https://doi.org/10.1002/ehf2.12592CrossRefPubMedPubMedCentral

327.

Ardell JL, Nier H, Hammer M, Southerland EM, Ardell CL, Beaumont E, KenKnight BH, Armour JA (2017) Defining the neural fulcrum for chronic vagus nerve stimulation: implications for integrated cardiac control. J Physiol 595:6887–6903. https://doi.org/10.1113/JP274678CrossRefPubMedPubMedCentral

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Autonomic control of ventricular function in health and disease: current state of the art

Abstract

Purpose

Methods

Results

Conclusions

Neu in den Fachgebieten Neurologie und Psychiatrie

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Schutz der Synapsen bei Alzheimer

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Cancer in pathologically confirmed multiple system atrophy

All orthostatic hypotension is neurogenic

A case of recurring perioperative circulatory arrest: mind the autonomic nervous system

Higher sympathetic transduction is independently associated with greater very short-term diastolic blood pressure variability in young healthy males and females

A case showing how hyperventilation may decrease blood pressure in neurogenic orthostatic hypotension

Associations between physical activity and autonomic function during deep breathing test: the Swedish CArdioPulmonary bioImage Study (SCAPIS)

Neu in den Fachgebieten Neurologie und Psychiatrie

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Schutz der Synapsen bei Alzheimer

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid